Gemfibrozil and Skin hypertrophy - a phase IV clinical study of FDA data

Summary:

Skin hypertrophy is reported as a side effect among people who take Gemfibrozil (gemfibrozil), especially for people who are male, 60+ old, also take Humira, and have Psoriasis.

The phase IV clinical study analyzes which people have Skin hypertrophy when taking Gemfibrozil. It is created by eHealthMe based on reports of 17,763 people who have side effects when taking Gemfibrozil from the FDA, and is updated regularly.

What is Gemfibrozil?

Gemfibrozil has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 18,213 Gemfibrozil users. Check the latest studies of Gemfibrozil.

What is Skin hypertrophy?

Skin hypertrophy (skin cells enlarges) is found to be associated with 594 drugs and 544 conditions by eHealthMe. Check the latest studies of Skin hypertrophy.

On Jul, 12, 2026

17,763 people reported to have side effects when taking Gemfibrozil.
Among them, 13 people (0.07%) have Skin hypertrophy.

Could Gemfibrozil cause Skin hypertrophy?

Among these 13 people:

What is the gender of people who have Skin hypertrophy when taking Gemfibrozil? *

female: 0.0 %
male: 100 %

What is the age of people who have Skin hypertrophy when taking Gemfibrozil? *

What are other drugs people take besides Gemfibrozil? *

What are other side effects people have besides Skin hypertrophy? *

Skin Fissures (a crack in the skin): 10 people, 76.92%
Borderline Glaucoma: 9 people, 69.23%
Onychomadesis (a periodic idiopathic shedding of the nails): 9 people, 69.23%
Hyperkeratosis (thickening of the outer layer of the skin): 9 people, 69.23%
Stress And Anxiety: 9 people, 69.23%
Psoriasis (immune-mediated disease that affects the skin): 9 people, 69.23%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 69.23%
High Blood Pressure: 9 people, 69.23%
Fall: 8 people, 61.54%
Eye Discharge: 8 people, 61.54%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 10 people, 76.92%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 61.54%
Pain: 8 people, 61.54%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Gemfibrozil and have Skin hypertrophy?

- Check whether Skin hypertrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemfibrozil:

Gemfibrozil (18,213 reports)

Browse all side effects of Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hypertrophy:

Skin hypertrophy (594 drugs)

Browse all the conditions that are associated with Skin hypertrophy:

Skin hypertrophy (544 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemfibrozil (the active ingredients of Gemfibrozil) and Gemfibrozil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.